# 10x Genomics share price today (10x Genomics, Inc., TXG)

> 10x Genomics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TXG · Healthcare · Health Information Services · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/txg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $67.52 (+342.8% in a year)
- Revenue (Jun 2026): $151 M (−12.6% on a year ago)
- Profit (Jun 2026): −$17.9 M (−151.9% on a year ago)
- Operating margin: −15.2% (−9.1 points on a year ago)
- ROE: −6%, FY25
- ROIC: −5.8%, against a 15.3% cost of capital: −21.1 points

Biggest thing to watch: the price has already been rising for 41 weeks, so timing is the risk more than the business. ## What is the 10x Genomics share price today? 10x Genomics, Inc.'s share price was $67.52 at the close on 4 November 2026. It has been rising for 41 weeks. That is 63.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $15 and $94, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 28 weeks in a row. Over the last 7.1 years the share price moved +29% while the S&P 500 moved +155%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does 10x Genomics pay? 10x Genomics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is 10x Genomics on? 10x Genomics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is 10x Genomics profitable? 10x Genomics, Inc. posted a net loss of $17.9 M in the Jun 2026 quarter. The full FY25 year was a loss of $43.5 M. That loss is 11.9% of the quarter's revenue. The same quarter a year earlier earned $34.5 M. 11 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$17.9 M, −151.9% on a year earlier. ## How much revenue does 10x Genomics make, and is it growing? 10x Genomics, Inc. reported $151 M of revenue in the Jun 2026 quarter, −12.6% on the same quarter a year earlier. Over 4 years it has grown 7.0% a year on average. The last full year, FY25, came in at $643 M. The last four reported quarters add to $617 M. FY25 revenue was $643 M, +5.2% on the year before. Recent pace: the last four quarters grew −4.1% on average, against 7.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −4.3%, against −1.2% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does 10x Genomics keep? 10x Genomics, Inc.'s operating margin was −15.2% in the Jun 2026 quarter, 9.1 percentage points lower than the same quarter a year ago. Across 5 years it has been between −32.3% and −10.8%. The latest quarter is within that range. Why the margin moved: operating margin changed −9.1 percentage points on the year while gross margin changed +2.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is 10x Genomics' profit turning into cash? 10x Genomics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $136 M of operating cash against −$43.5 M of profit. After $5.9 M of spending on assets, $130 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does 10x Genomics' cash go? 10x Genomics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $66.9 M on assets over the last 3 years. Averaged over those years that is 3.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $66.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is 10x Genomics' P/E ratio, and how does it compare with its own history? 10x Genomics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values 10x Genomics, Inc. at 13.7× its FY25 revenue of $643 M. The P/E comes back here once profit turns positive. ## Is the 10x Genomics business getting better or worse? 10x Genomics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does 10x Genomics earn on its capital? 10x Genomics, Inc. earned a ROE of −6% in FY25. That is up from a low of −34% in FY23. Its return on capital used (ROIC) is 21.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −6.8% net margin and 0.62× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −6.8% net margin × 0.62× asset turnover × 1.31× leverage (assets divided by equity) ≈ −5.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −5.8% − 15.3% = −21.1 percentage points. The 15.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does 10x Genomics have too much debt? 10x Genomics, Inc. has total debt of $78.8 M against shareholder equity of $826 M as of Jun 2026, so its debt is 0.10× its equity, which is very little. Year by year, that ratio went from 0.10 in FY21 to 0.11 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the 10x Genomics shareholding pattern? 10.8% of 10x Genomics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 3.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is 10x Genomics from balance-sheet trouble? For 10x Genomics, Inc., the Z-score is 5.75. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.75 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does 10x Genomics rank in its industry? 45.2 out of 100, rank 15 of 29 in Health Information Services, with 64% of the evidence available. 10x Genomics, Inc. scores 45.2 out of 100 against the 29 companies it is compared with in Health Information Services, ranking 15. Relative strength against the index is 76.3%, and revenue and profit growth are weak. The four parts add up to the total exactly: 13.9 + 6.2 + 11.1 + 14 = 45.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is 10x Genomics compared with? 10x Genomics ranks 15 of 29 Health Information Services companies on the 4-Factor Sector Score, with 45.2 out of 100. 1. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) HNGE · leader · Most evidence points up · 64% evidence 72.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 49.7% · Profit n/a · Operating margin change 436.5 points · 62% evidence Capital efficiency 19.0/25 · ROCE 27.1% · Operating margin 19% · 76% evidence Valuation 9.3/20 · P/E 59.8× · PEG n/a · 15% evidence Relative strength 17.3/20 · Lead over its industry 40.2% · Lead over S&P 500 78.7% · 1 year 171.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.5 + 19 + 9.3 + 17.3 = 72.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Veeva Systems Inc.](https://www.sectoralpha.in/us/stocks/veev) VEEV · breaking out · Most evidence points up · 85% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 16.5% · Profit 25.2% · Operating margin change 0.9 points · 95% evidence Capital efficiency 18.8/25 · ROCE 13.6% · Operating margin 29.6% · 76% evidence Valuation 13.0/20 · P/E 32.6× · PEG 1.3 · 65% evidence Relative strength 16.1/20 · Lead over its industry 4% · Lead over S&P 500 34.9% · 1 year 5.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.9 + 18.8 + 13 + 16.1 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) HTFL · leader · Evidence leans up · 61% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 43.2% · Profit n/a · Operating margin change 3.7 points · 62% evidence Capital efficiency 4.5/25 · ROCE -24.2% · Operating margin -27.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.0/20 · Lead over its industry 22.7% · Lead over S&P 500 57.9% · 1 year 73.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 4.5 + 10 + 19 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) WAY · breaking out · Evidence leans up · 81% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 19.4% · Profit 58.8% · Operating margin change 0.4 points · 83% evidence Capital efficiency 12.2/25 · ROCE 5.2% · Operating margin 24.4% · 76% evidence Valuation 15.6/20 · P/E 29.2× · PEG 0.64 · 65% evidence Relative strength 8.7/20 · Lead over its industry -18.4% · Lead over S&P 500 7.6% · 1 year -18% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.7 + 12.2 + 15.6 + 8.7 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Schrödinger, Inc.](https://www.sectoralpha.in/us/stocks/sdgr) SDGR · leader · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 8.8% · Profit n/a · Operating margin change 26 points · 62% evidence Capital efficiency 4.6/25 · ROCE -32.9% · Operating margin -70.6% · 76% evidence Valuation 11.2/20 · P/E -22.3× · PEG n/a · 15% evidence Relative strength 18.9/20 · Lead over its industry 22.7% · Lead over S&P 500 57.8% · 1 year 60.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 4.6 + 11.2 + 18.9 = 55.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) HQY · turning · Evidence leans up · 85% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 7.4% · Profit 62.3% · Operating margin change 0.5 points · 95% evidence Capital efficiency 16.1/25 · ROCE 11.4% · Operating margin 28.4% · 76% evidence Valuation 11.6/20 · P/E 35.6× · PEG 1.53 · 65% evidence Relative strength 5.8/20 · Lead over its industry -14.5% · Lead over S&P 500 12.5% · 1 year 16.1% · 100% evidence · 5 of 12 weeks ahead Exact sum: 21.4 + 16.1 + 11.6 + 5.8 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) DOCS · breaking out · Evidence leans up · 81% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.5/35 · Revenue 11.2% · Profit -28.6% · Operating margin change -16.3 points · 83% evidence Capital efficiency 20.9/25 · ROCE 21.6% · Operating margin 21.5% · 76% evidence Valuation 10.8/20 · P/E 22.7× · PEG 1.74 · 65% evidence Relative strength 10.1/20 · Lead over its industry -16.5% · Lead over S&P 500 9.8% · 1 year -36.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.5 + 20.9 + 10.8 + 10.1 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [NRC Health](https://www.sectoralpha.in/us/stocks/nrc) NRC · turning · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.6/35 · Revenue -0.7% · Profit -68.4% · Operating margin change -24.4 points · 62% evidence Capital efficiency 18.4/25 · ROCE 24.3% · Operating margin -0.2% · 76% evidence Valuation 9.7/20 · P/E 45× · PEG n/a · 15% evidence Relative strength 14.4/20 · Lead over its industry 2.1% · Lead over S&P 500 33.8% · 1 year 84.1% · 100% evidence · 7 of 12 weeks ahead Exact sum: 9.6 + 18.4 + 9.7 + 14.4 = 52.1 · What this means: Relative strength against the index is 33.8%, and revenue and profit growth are weak. 9. [BrightSpring Health Services, Inc.](https://www.sectoralpha.in/us/stocks/btsg) BTSG · turning · Too little evidence to rank firmly · 56% evidence 51.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.0/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 39% evidence Capital efficiency 12.6/25 · ROCE 10.1% · Operating margin 3.4% · 76% evidence Valuation 10.0/20 · P/E 39.7× · PEG n/a · 15% evidence Relative strength 9.0/20 · Lead over its industry -2.5% · Lead over S&P 500 27.6% · 1 year 110.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20 + 12.6 + 10 + 9 = 51.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) PHR · turning · Evidence leans down · 67% evidence 49.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 12.7% · Profit n/a · Operating margin change 7.2 points · 71% evidence Capital efficiency 9.5/25 · ROCE 4.3% · Operating margin 5.9% · 76% evidence Valuation 9.0/20 · P/E 63.5× · PEG n/a · 15% evidence Relative strength 6.8/20 · Lead over its industry -24.7% · Lead over S&P 500 -0.6% · 1 year -40.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 23.7 + 9.5 + 9 + 6.8 = 49 · What this means: Earnings are strong; relative strength in its sector is -24.7% and the one-year return is -40.1%. 11. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) TEM · breaking out · Evidence leans down · 64% evidence 48.5 out of 100 Growth Capital Valuation Relative
12. [Certara, Inc.](https://www.sectoralpha.in/us/stocks/cert) CERT · leader · Evidence leans down · 64% evidence 46.0 out of 100 Growth Capital Valuation Relative
13. [HealthStream, Inc.](https://www.sectoralpha.in/us/stocks/hstm) HSTM · leader · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
14. [Omada Health, Inc.](https://www.sectoralpha.in/us/stocks/omda) OMDA · quiet · Evidence leans down · 64% evidence 45.2 out of 100 Growth Capital Valuation Relative
15. 10x Genomics, Inc. this page TXG · leader · Evidence leans down · 64% evidence 45.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue -4.3% · Profit n/a · Operating margin change -9.1 points · 62% evidence Capital efficiency 6.2/25 · ROCE -9.6% · Operating margin -15.2% · 76% evidence Valuation 11.1/20 · P/E -16.9× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 41.1% · Lead over S&P 500 76.3% · 1 year 342.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 13.9 + 6.2 + 11.1 + 14 = 45.2 · What this means: Relative strength against the index is 76.3%, and revenue and profit growth are weak. 16. [American Well Corporation](https://www.sectoralpha.in/us/stocks/amwl) AMWL · losing its lead · Evidence leans down · 61% evidence 45.1 out of 100 Growth Capital Valuation Relative
17. [Spok Holdings, Inc.](https://www.sectoralpha.in/us/stocks/spok) SPOK · turning · Evidence leans down · 81% evidence 44.6 out of 100 Growth Capital Valuation Relative
18. [Omnicell, Inc.](https://www.sectoralpha.in/us/stocks/omcl) OMCL · turning · Evidence leans down · 71% evidence 43.3 out of 100 Growth Capital Valuation Relative
19. [Carlsmed, Inc.](https://www.sectoralpha.in/us/stocks/carl) CARL · leader · Evidence leans down · 61% evidence 43.1 out of 100 Growth Capital Valuation Relative
20. [Teladoc Health, Inc.](https://www.sectoralpha.in/us/stocks/tdoc) TDOC · turning · Evidence leans down · 61% evidence 43.1 out of 100 Growth Capital Valuation Relative
21. [Privia Health Group, Inc.](https://www.sectoralpha.in/us/stocks/prva) PRVA · turning · Evidence leans down · 81% evidence 42.3 out of 100 Growth Capital Valuation Relative
22. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) EVH · turning · Evidence leans down · 64% evidence 38.0 out of 100 Growth Capital Valuation Relative
23. [Claritev Corporation](https://www.sectoralpha.in/us/stocks/ctev) CTEV · quiet · Evidence leans down · 64% evidence 37.4 out of 100 Growth Capital Valuation Relative
24. [SOPHiA GENETICS SA](https://www.sectoralpha.in/us/stocks/soph) SOPH · losing its lead · Evidence leans down · 61% evidence 36.4 out of 100 Growth Capital Valuation Relative
25. [GoodRx Holdings, Inc.](https://www.sectoralpha.in/us/stocks/gdrx) GDRX · losing its lead · Most evidence points down · 81% evidence 34.9 out of 100 Growth Capital Valuation Relative
26. [Simulations Plus, Inc.](https://www.sectoralpha.in/us/stocks/slp) SLP · Too little evidence to rank firmly · 44% evidence 56.3 out of 100 Growth Capital Valuation Relative
27. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) TALK · Too little evidence to rank firmly · 44% evidence 48.4 out of 100 Growth Capital Valuation Relative
28. [Weave Communications, Inc.](https://www.sectoralpha.in/us/stocks/weav) WEAV · Too little evidence to rank firmly · 41% evidence 47.7 out of 100 Growth Capital Valuation Relative
29. [TruBridge, Inc.](https://www.sectoralpha.in/us/stocks/tbrg) TBRG · Too little evidence to rank firmly · 31% evidence 42.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Health Information Services](https://www.sectoralpha.in/us/sectors/health-information-services), all 29 compared on one page. ## Which companies are close to 10x Genomics in size? 10x Genomics is the 6th largest of 30 Health Information Services companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Tempus AI, Inc., Hinge Health, Inc. and HealthEquity, Inc. Just below it: Doximity, Inc., Waystar Holding Corp. and HeartFlow, Inc. ### Health Information Services companies close in size

1. [Tempus AI, Inc.](https://www.sectoralpha.in/us/stocks/tem) $13.8 billion
2. [Hinge Health, Inc.](https://www.sectoralpha.in/us/stocks/hnge) $9.8 billion
3. [HealthEquity, Inc.](https://www.sectoralpha.in/us/stocks/hqy) $9 billion
4. 10x Genomics, Inc. $8.8 billion
5. [Doximity, Inc.](https://www.sectoralpha.in/us/stocks/docs) $6.2 billion
6. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) $5.7 billion
7. [HeartFlow, Inc.](https://www.sectoralpha.in/us/stocks/htfl) $4.9 billion

[All 30 Health Information Services companies, largest first](https://www.sectoralpha.in/us/sectors/health-information-services#all-companies)

### Companies close in size in other industries

1. [Kinsale Capital Group, Inc.](https://www.sectoralpha.in/us/stocks/knsl) $8.8 billion · Insurance - Property & Casualty
2. [Prosperity Bancshares, Inc.](https://www.sectoralpha.in/us/stocks/pb) $8.8 billion · Banks - Regional
3. 10x Genomics, Inc. $8.8 billion
4. [AECOM](https://www.sectoralpha.in/us/stocks/acm) $8.8 billion · Engineering & Construction
5. [Primerica, Inc.](https://www.sectoralpha.in/us/stocks/pri) $8.8 billion · Insurance - Life

## What else do people ask about 10x Genomics? ### What were 10x Genomics's latest quarterly results? 10x Genomics, Inc. reported revenue of $151 M and a net loss of $17.9 M for the Jun 2026 quarter. Revenue fell 12.6% and profit fell 151.9% compared with a year earlier. Earnings per share were −$0.14. The operating margin was −15.2%, 9.1 percentage points lower than a year earlier (as of 4 November 2026). ### What is 10x Genomics's market cap? 10x Genomics, Inc.'s market capitalisation is $8.8 B at a stock price of $67.52. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is 10x Genomics performing? 10x Genomics, Inc.'s share price has been rising for 41 weeks. In its latest quarter, revenue fell 12.6% and profit fell 151.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 28 weeks running (as of 4 November 2026). ### Will 10x Genomics's stock price go up? This page does not forecast 10x Genomics, Inc.'s stock price. What it shows instead: the stock price is $67.52, and it has been rising for 41 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is 10x Genomics in its business cycle? 10x Genomics, Inc.'s FY25 operating margin was −15.6%, against a 5-year range of −32.3% to −10.8%: the middle of its own range, neither a peak nor a low. The latest quarter was −15.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the 10x Genomics story? Biggest thing to watch: the price has already been rising for 41 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is 10x Genomics a stock worth studying right now? What the numbers show: 10x Genomics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.